All articles by Justine Ra

Justine Ra

Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.

Expanding diagnostic and biomarker options to improve MASH clinical trials

With diagnostics being integral in the detection, confirmation, and monitoring of disease, the lack of adequate and available diagnostics for…
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight

Amgen has announced a total revenue of $8.5bn in Q3 2024, a 23% increase from a $6.9bn revenue in the…
LEO’s Adbry demonstrates long-term efficacy in atopic dermatitis

LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s…
Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic

Thermo Fisher Scientific has announced that its in vitro diagnostic test, Oncomine, has won US Food and Drug Administration (FDA)…
Sage lays off 55% of R&D workforce and refocuses pipeline

After a series of mid-stage clinical trial failures, Sage Therapeutics has announced that it will jettison 165 employees, which totals…

South Korean company Dong-A ST wins FDA approval for Stelara biosimilar

South Korea-based Dong-A ST has received a US Food and Drug Administration (FDA) approval for Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar that…
Neuvivo makes bid to enter ALS arena with immunotherapy candidate

Neuvivo has submitted a New Drug Application (NDA) for its investigational amyotrophic lateral sclerosis (ALS) immunotherapy to the US Food…
Triveni scores $115m to expand immunology pipeline

Triveni Bio has secured $115m in a Series B funding round to advance its preclinical antibody candidates for immunological and…
FDA greenlights Regeneron’s Dupixent for the treatment of COPD

With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US…
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms…